Immucell Corp
Research Immucell Corp (ICCC) on Bullrun: valuation model: 70.5% overvalued, market cap USD 87.19M, P/E 114.6. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerICCC
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal70.5% overvalued
- Market capUSD 87.19M
- P/E114.6
- Financial periodQ2 2026
- RevenueUSD 7.19M
- Net incomeUSD 1.83M
- Free cash flowUSD 2.29M
- Gross margin33.9%
Valuation Snapshot
Bullrun's latest valuation model marks Immucell Corp as 70.5% overvalued; latest market cap is USD 87.19M; P/E is 114.6.
Peer valuation comparison
Latest P/E is 114.56x versus a Healthcare sector median of 24.6x (365.7% above).
Latest P/E is 114.56x versus a United States median of 23.85x (380.3% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 27.64M | -USD 1.04M | USD 1.22M | 41.4% | -0.12 | USD 3.81M | USD 9.10M | USD 27.06M |
| FY2024 | USD 26.49M | -USD 2.16M | -USD 107.82K | 30.0% | -0.26 | USD 3.76M | USD 10.54M | USD 27.52M |
| FY2023 | USD 17.47M | -USD 5.78M | -USD 6.57M | 22.1% | -0.75 | USD 978.74K | USD 10.43M | USD 24.99M |
| FY2022 | USD 18.57M | -USD 2.49M | -USD 5.52M | 41.2% | -0.32 | USD 5.79M | USD 19.13M | USD 30.38M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 87.19M | 114.6 | n/a | n/a |
| 2025 | 2025-12-31 | USD 55.63M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 46.24M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 39.45M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 47.26M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 61.94M | n/a | n/a | n/a |
About Immucell Corp
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Immucell Corp overvalued or undervalued?
Bullrun's valuation model currently marks Immucell Corp as 70.5% overvalued.
What is Immucell Corp's market cap?
Immucell Corp's market capitalization is USD 87.19M.
What is Immucell Corp's P/E ratio?
Immucell Corp's price-to-earnings (P/E) ratio is 114.6.
What does Immucell Corp do?
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus.